These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 19517320)

  • 1. [Cardiology 2009].
    Hoppe UC
    Dtsch Med Wochenschr; 2009 Jun; 134(25-26):1309-11. PubMed ID: 19517320
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical-scientific notes.
    Dick RJ; Byron KA; Dear AE
    Intern Med J; 2012 Oct; 42 Suppl 5():7-8. PubMed ID: 23035675
    [No Abstract]   [Full Text] [Related]  

  • 3. CYP2C19 genotype and outcomes of clopidogrel treatment.
    Geisler T; Bigalke B; Schwab M
    N Engl J Med; 2011 Feb; 364(5):481; author reply 482. PubMed ID: 21288102
    [No Abstract]   [Full Text] [Related]  

  • 4. Clopidogrel: to test or not to test? That is the question--still.
    Cannon CP
    Clin Chem; 2011 May; 57(5):659-61. PubMed ID: 21402801
    [No Abstract]   [Full Text] [Related]  

  • 5. Clopidogrel, genetics, and drug responsiveness.
    Freedman JE; Hylek EM
    N Engl J Med; 2009 Jan; 360(4):411-3. PubMed ID: 19164193
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytochrome P-450 polymorphisms and response to clopidogrel.
    Taubert D; Bouman HJ; van Werkum JW
    N Engl J Med; 2009 May; 360(21):2249-50; author reply 2251. PubMed ID: 19458375
    [No Abstract]   [Full Text] [Related]  

  • 7. ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association.
    ; ; ; Holmes DR; Dehmer GJ; Kaul S; Leifer D; O'Gara PT; Stein CM
    Circulation; 2010 Aug; 122(5):537-57. PubMed ID: 20585015
    [No Abstract]   [Full Text] [Related]  

  • 8. Clopidogrel resistance - a clear problem with an unclear solution.
    Bansilal S; Bhatt DL
    Indian Heart J; 2012; 64(4):353-5. PubMed ID: 22929816
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytochrome P450 2C19 polymorphism and clopidogrel after MI.
    Bhattacharyya S; Rakhit R
    Lancet; 2009 Apr; 373(9670):1171; author reply 1172-3. PubMed ID: 19345825
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytochrome P450 2C19 polymorphism and clopidogrel after MI.
    Miao J; Liu R; Li Z
    Lancet; 2009 Apr; 373(9670):1171-2; author reply 1172-3. PubMed ID: 19345824
    [No Abstract]   [Full Text] [Related]  

  • 11. Platelet inhibitors: update on clopidogrel (Plavix) and the recently approved prasugrel (Effient).
    Wynn RL
    Gen Dent; 2010; 58(1):7-9. PubMed ID: 20129886
    [No Abstract]   [Full Text] [Related]  

  • 12. Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines.
    Steinhubl SR
    Circulation; 2010 Feb; 121(4):481-3. PubMed ID: 20083686
    [No Abstract]   [Full Text] [Related]  

  • 13. Putting genomics into practice.
    Holmes MV; Casas JP; Hingorani AD
    BMJ; 2011 Aug; 343():d4953. PubMed ID: 21816737
    [No Abstract]   [Full Text] [Related]  

  • 14. Personalized medicine and antiplatelet therapy: ready for prime time?
    Verstuyft C; Simon T; Kim RB
    Eur Heart J; 2009 Aug; 30(16):1943-63. PubMed ID: 19638479
    [No Abstract]   [Full Text] [Related]  

  • 15. Omeprazole: a possible new candidate influencing the antiplatelet effect of clopidogrel.
    Gurbel PA; Lau WC; Tantry US
    J Am Coll Cardiol; 2008 Jan; 51(3):261-3. PubMed ID: 18206733
    [No Abstract]   [Full Text] [Related]  

  • 16. Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit?
    Bhatt DL
    JAMA; 2009 Aug; 302(8):896-7. PubMed ID: 19706866
    [No Abstract]   [Full Text] [Related]  

  • 17. [A current problem for regulators. Clopidogrel and pharmacokinetics].
    Zündorf I; Dingermann T
    Pharm Unserer Zeit; 2009; 38(4):360-7. PubMed ID: 19572363
    [No Abstract]   [Full Text] [Related]  

  • 18. Cytochrome p-450 polymorphisms and response to clopidogrel.
    Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias W; Braunwald E; Sabatine MS
    N Engl J Med; 2009 Jan; 360(4):354-62. PubMed ID: 19106084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P-450 polymorphisms and response to clopidogrel.
    Miao J; Liu R; Li Z
    N Engl J Med; 2009 May; 360(21):2250-1. PubMed ID: 19469033
    [No Abstract]   [Full Text] [Related]  

  • 20. Antiplatelet therapy after percutaneous coronary intervention: Should another regimen be "TAPT?".
    Croce K
    Circ Cardiovasc Interv; 2010 Feb; 3(1):3-5. PubMed ID: 20160184
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.